170 related articles for article (PubMed ID: 31727629)
1. Prophylactic
Li C; Course MM; McNeish IA; Drescher CW; Valdmanis PN; Lieber A
Cancer Res; 2020 Feb; 80(3):549-560. PubMed ID: 31727629
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.
Ben Nasr M; Tezza S; D'Addio F; Mameli C; Usuelli V; Maestroni A; Corradi D; Belletti S; Albarello L; Becchi G; Fadini GP; Schuetz C; Markmann J; Wasserfall C; Zon L; Zuccotti GV; Fiorina P
Sci Transl Med; 2017 Nov; 9(416):. PubMed ID: 29141886
[TBL] [Abstract][Full Text] [Related]
3. In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors.
Richter M; Saydaminova K; Yumul R; Krishnan R; Liu J; Nagy EE; Singh M; Izsvák Z; Cattaneo R; Uckert W; Palmer D; Ng P; Haworth KG; Kiem HP; Ehrhardt A; Papayannopoulou T; Lieber A
Blood; 2016 Nov; 128(18):2206-2217. PubMed ID: 27554082
[TBL] [Abstract][Full Text] [Related]
4. Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements.
Wang H; Georgakopoulou A; Li C; Liu Z; Gil S; Bashyam A; Yannaki E; Anagnostopoulos A; Pande A; Izsvák Z; Papayannopoulou T; Lieber A
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814708
[TBL] [Abstract][Full Text] [Related]
5. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.
Wang H; Georgakopoulou A; Psatha N; Li C; Capsali C; Samal HB; Anagnostopoulos A; Ehrhardt A; Izsvák Z; Papayannopoulou T; Yannaki E; Lieber A
J Clin Invest; 2019 Feb; 129(2):598-615. PubMed ID: 30422819
[TBL] [Abstract][Full Text] [Related]
6. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Delivery of an Adenoviral Vector Carrying the
Nakagawa S; Serada S; Kakubari R; Hiramatsu K; Sugase T; Matsuzaki S; Matsuzaki S; Ueda Y; Yoshino K; Ohkawara T; Fujimoto M; Kishimoto T; Kimura T; Naka T
Mol Cancer Ther; 2018 Sep; 17(9):1941-1950. PubMed ID: 29891489
[TBL] [Abstract][Full Text] [Related]
8. Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.
Morton JJ; Keysar SB; Perrenoud L; Chimed TS; Reisinger J; Jackson B; Le PN; Nieto C; Gomez K; Miller B; Gao D; Somerset H; Wang XJ; Jimeno A
Mol Carcinog; 2018 Nov; 57(11):1651-1663. PubMed ID: 30129680
[TBL] [Abstract][Full Text] [Related]
9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
10. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
11. Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source.
Hess NJ; Lindner PN; Vazquez J; Grindel S; Hudson AW; Stanic AK; Ikeda A; Hematti P; Gumperz JE
Front Immunol; 2020; 11():573406. PubMed ID: 33193358
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
16. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.
Persson J; Beyer I; Yumul R; Li Z; Kiem HP; Roffler S; Lieber A
PLoS One; 2011; 6(7):e22303. PubMed ID: 21779410
[TBL] [Abstract][Full Text] [Related]
17. A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy.
Kao RL; Truscott LC; Chiou TT; Tsai W; Wu AM; De Oliveira SN
Hum Gene Ther; 2019 Apr; 30(4):413-428. PubMed ID: 30860401
[TBL] [Abstract][Full Text] [Related]
18. Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.
Li C; Mishra AS; Gil S; Wang M; Georgakopoulou A; Papayannopoulou T; Hawkins RD; Lieber A
Mol Ther; 2019 Dec; 27(12):2195-2212. PubMed ID: 31494053
[TBL] [Abstract][Full Text] [Related]
19. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
Ahmad G; Mackenzie GG; Egan J; Amiji MM
Mol Cancer Ther; 2019 Nov; 18(11):1961-1972. PubMed ID: 31439714
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
